Eysker M, Boersema J H, Cornelissen J B, Kloosterman A, Kooyman F N
Department of Parasitology and Tropical Veterinary Medicine, Utrecht University, Netherlands.
Vet Parasitol. 1996 Jan;61(1-2):61-71. doi: 10.1016/0304-4017(95)00822-5.
The residual effect of a 0.2 mg kg-1 injectable formulation of moxidectin against lungworm and gastrointestinal nematodes in cattle was studied in a grazing experiment in the Netherlands. Five groups of four calves were grazed between May and October 1991 and one similar group was used as permanently housed control group for the evaluation of the development of immunity against lungworm by challenge infections with 5000 larvae of all six groups. The main parameter used to determine the residual effect for lungworm was faecal larval counts. Additional information was derived from pasture larval counts, enzyme-linked immunosorbent assay (ELISA), respiration frequency, coughing score and, particularly for evaluating development of immunity, worm counts. For gastrointestinal nematode infections faecal egg counts and larval differentiation of faecal cultures were the main parameters used. Pasture larval counts and an ELISA for Ostertagia and Cooperia were used as additional parameters. In three treated groups lungworm larvae (re)appeared in the faeces after 67, 95 and 119 days, respectively. This implies that a 100% residual effect did not last longer than 67-21 = 46 days. The treated group with patency starting on Day 95 was exposed to extremely high infection pressure and the ELISA indicated some host-parasite interactions from 2-4 weeks after treatment. Thus some interaction between moxidectin treatment and high infection pressure delayed the onset of patency in comparison to another treated group under much lower infection pressure. In all treated groups, including the one under high infection pressure, lungworm disease was prevented and the worm counts demonstrated development of immunity. In contrast, severe lungworm disease occurred in two control groups grazing together with the 'high infection pressure' treated group. The faecal egg counts and differentiation of larvae from faecal cultures demonstrated a 100% residual effect of at least 3 weeks and indicated a high residual effect of approximately 5 weeks against Ostertagia. Moxidectin suppressed Cooperia faecal egg counts for over 98% and the results indicated a more than 95% residual effect on faecal egg output during 2-3 weeks. The ELISA results were indicative for a delay of 2 weeks in the acquisition of gastrointestinal nematode infections following moxidectin treatment.
在荷兰进行的一项放牧试验中,研究了莫昔克丁0.2毫克/千克注射剂对牛肺线虫和胃肠道线虫的残留效果。1991年5月至10月期间,将五组每组四头犊牛放牧,另一组类似的犊牛作为永久圈养的对照组,用于通过对所有六组犊牛接种5000条幼虫来评估其对肺线虫免疫力的发展情况。用于确定肺线虫残留效果的主要参数是粪便幼虫计数。其他信息来自牧场幼虫计数、酶联免疫吸附测定(ELISA)、呼吸频率、咳嗽评分,特别是为了评估免疫力的发展,还包括虫体计数。对于胃肠道线虫感染,粪便虫卵计数和粪便培养物中的幼虫鉴别是主要使用的参数。牧场幼虫计数以及针对奥斯特他线虫和古柏线虫的ELISA用作附加参数。在三个治疗组中,肺线虫幼虫分别在67、95和119天后在粪便中再次出现。这意味着100%的残留效果持续时间不超过67 - 21 = 46天。在第95天开始出现排虫的治疗组受到极高的感染压力,ELISA表明在治疗后2 - 4周存在一些宿主 - 寄生虫相互作用。因此,与另一个处于低得多感染压力下的治疗组相比,莫昔克丁治疗与高感染压力之间的某些相互作用延迟了排虫的开始。在所有治疗组中,包括处于高感染压力下的组,肺线虫病均得到预防,虫体计数表明免疫力得到发展。相比之下,与“高感染压力”治疗组一起放牧的两个对照组发生了严重的肺线虫病。粪便虫卵计数和粪便培养物中幼虫的鉴别表明至少3周有100%的残留效果,并且表明对奥斯特他线虫约5周有高残留效果。莫昔克丁抑制古柏线虫粪便虫卵计数超过98%,结果表明在2 - 3周内对粪便虫卵排出有超过95%的残留效果。ELISA结果表明,莫昔克丁治疗后获得胃肠道线虫感染的时间延迟了2周。